ACE and chronic kidney disease: Furthermore, long-term studies of sACE2 levels are required in at-risk populations (e.g., those with and without hypertension and chronic kidney disease) and in patients receiving treatments that may affect sACE2 activity or concentration (i.e., ACE inhibitors or angiotensin receptor blockers).